Registry to track outcomes in patients with KRAS G12R altered advanced pancreatic cancer treated with MEK inhibitors
A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy
This study is tracking how well different combination treatments using MEK inhibitors work for people with advanced pancreatic cancer that has a specific KRAS mutation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical College of Wisconsin Academic / other |
| Locations | 1 site (Milwaukee, Wisconsin) |
| Trial ID | NCT05630989 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and analyze patient data to evaluate the safety and efficacy of various MEK inhibitor-based combination therapies for individuals with KRAS G12R mutated advanced pancreatic ductal adenocarcinoma. It will involve a retrospective and prospective review of patient medical records, focusing on molecular profiling results and treatment responses. Key outcome measures will include tumor response, patient survival, and treatment toxicity, with the goal of assessing the feasibility of future clinical trials involving these therapies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with advanced pancreatic ductal adenocarcinoma harboring the KRAS G12R mutation.
Not a fit: Patients with pancreatic ductal adenocarcinoma who do not have the KRAS G12R mutation or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for patients with a specific genetic mutation in pancreatic cancer.
How similar studies have performed: While this approach is focused on a specific mutation and treatment combination, similar studies have shown promise in precision oncology, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years. 2. Diagnosis of advanced pancreatic ductal adenocarcinoma as determined by the treating physician or tumor board. 3. Tumor must have KRAS G12R mutation, as determined by a next generation sequencing (NGS) panel or circulating tumor DNA panel of choice of the treating physician. 4. Ability to understand a written informed consent document and the willingness to sign it. Exclusion Criteria: 1. Age \<18 years. 2. Primary cancer diagnosis other than advanced pancreatic ductal adenocarcinoma 3. Tumor does not have a KRAS G12R mutation.
Where this trial is running
Milwaukee, Wisconsin
- Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin, United States (Recruiting)
Study contacts
- Principal investigator: Mandana Kamgar, MD, MPH — Medical College of Wisconsin
- Study coordinator: Mandana Kamgar, MD, MPH
- Email: mkamgar@mcw.edu
- Phone: 414-805-4600
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.